#	Pagina
attuale pagina	/open-h2020/projects/195153/index.html
-1	/open-h2020/projects/222688/index.html
-2	/open-h2020/projects/209483/index.html
-3	/open-h2020/projects/213393/index.html
-4	/open-h2020/per-topic/ecomic/list/index.html
-5	/open-h2020/projects/202888/index.html
-6	/open-h2020/projects/208741/results.html
-7	/open-h2020/projects/224357/index.html
-8	/open-h2020/projects/220379/index.html
-9	/open-h2020/per-topic/traitement/list/index.html
-10	/open-h2020/projects/199020/deliverables.html

Opendata, web and dolomites

GutILC3

Cell-cell interactions critical to ILC3 function in the human gut

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

GutILC3 project word cloud

Explore the words cloud of the GutILC3 project. It provides you a very rough idea of what is the project "GutILC3" about.

inappropriate provides exact interactions training techniques interaction 22 degree prospects mouse modulating papers materials unravel inflammation ilc3 critical optimal intestine truly innate interestingly pinpoint discovered gamma possibilities group cd4 ensures excellent suitable human direct infrastructure il utilizes crosstalk unknown intestinal purpose host patient progression cells record 17 seem reporting etiology me crc molecules track therapies extensive dramatically microbes building interacting skill genetically colorectal insights mucosal monitoring players homeostasis risk feasibility producing ultimate immune colitis cancer manner susceptible mononuclear inflammatory ifn society hosting translational ibd cellular disease lymphoid conferring bowel ilcs model phagocytes maintaining career therapy

Project "GutILC3" data sheet

The following table provides information about the project.

Coordinator	KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Total cost	173˙857 €
EC max contribution	173˙857 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2015
Duration (year-month-day)	from 2015-04-01 to 2017-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	coordinator	173˙857.00

Map

Project objective

Inflammatory bowel disease (IBD), conferring a dramatically increased risk for development of colorectal cancer (CRC), results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. However, the exact etiology of IBD is unknown. Building up on high impact papers from the host group reporting on the recently discovered innate lymphoid cells (ILCs) as key players in mucosal inflammation, I now aim to unravel the role for ILCs in IBD and CRC. Interestingly, while the IL-22 producing ILC3 seem to be crucial in maintaining intestinal homeostasis, the IL-17 and IFN-gamma-producing ILCs can cause inflammation in a mouse model of colitis and are present in human IBD. Furthermore, ILCs were recently described to be involved in modulating immune responses, by interacting with CD4 T cells and mononuclear phagocytes in the mouse intestine. I aim to identify critical pathways in the crosstalk of ILC3 with other immune cells in the human intestine. The ultimate purpose is to assess how these interactions affect immune homeostasis and disease progression in IBD and CRC. We will pinpoint crucial interaction molecules and cellular processes that can be used for monitoring current therapies as well as finding new therapy targets for IBD and CRC. This truly translational proposal utilizes, in an optimal manner, unique state-of-the-art techniques and patient materials to provide novel insights into the etiology of IBD and CRC. The excellent track record of the hosting group, the highly suitable infrastructure provided by the host institution and my own extensive research experience ensures a high degree of feasibility. Furthermore, this project provides excellent training opportunities, skill advancement possibilities and career prospects for me and its results are expected to have a direct impact on the European society.

Publications

List of publications.
year	authors and title	journal	last update
2015	V. Konya, J. MjÃ¶sberg Innate Lymphoid Cells in Graft-Versus-Host Disease published pages: 2795-2801, ISSN: 1600-6135, DOI: 10.1111/ajt.13394	American Journal of Transplantation 15/11	2019-07-23
2016	Ã…sa K BjÃ¶rklund, Marianne Forkel, Simone Picelli, Viktoria Konya, Jakob Theorell, Danielle Friberg, Rickard Sandberg, Jenny MjÃ¶sberg The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing published pages: 451-460, ISSN: 1529-2908, DOI: 10.1038/ni.3368	Nature Immunology 17/4	2019-07-23
2016	Viktoria Konya, Jenny MjÃ¶sberg Lipid mediators as regulators of human ILC2 function in allergic diseases published pages: 36-42, ISSN: 0165-2478, DOI: 10.1016/j.imlet.2016.07.006	Immunology Letters 179	2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GUTILC3" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GUTILC3" are provided by the European Opendata Portal: CORDIS opendata.